Based on the Arch Biopartners Inc stock forecast from 0 analysts, the average analyst target price for Arch Biopartners Inc is not available over the next 12 months. Arch Biopartners Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Arch Biopartners Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Arch Biopartners Inc’s stock price was CAD 1.24. Arch Biopartners Inc’s stock price has changed by +11.71% over the past week, +14.81% over the past month and -57.97% over the last year.
No recent analyst target price found for Arch Biopartners Inc
No recent average analyst rating found for Arch Biopartners Inc
Company Overview Arch Biopartners Inc
Arch Biopartners Inc., a biotechnology company, engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is based in Toronto, Canada. Address: 27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5 Read Less
Arch Biopartners Inc., a biotechnology company, engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys, which result...Read More
N/A
N/A
0
N/A
CAD
Canada
Adjusted Closing Price for Arch Biopartners Inc (ARCH:CA)
Loading...
Unadjusted Closing Price for Arch Biopartners Inc (ARCH:CA)
Loading...
Share Trading Volume for Arch Biopartners Inc Shares
Loading...
Compare Performance of Arch Biopartners Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for ARCH:CA
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Arch Biopartners Inc (Sector: Biotechnology )
Frequently Asked Questions About Arch Biopartners Inc (ARCH:CA) Stock
Stock Target Advisor's fundamental analysis for Arch Biopartners Inc's stock is Neutral.
Unfortunately we do not have enough data on ARCH:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ARCH:CA's stock to indicate what its average analyst target is.
ARCH:CA stock's Price/Earning ratio is 220.00.
Our analysis grades ARCH:CA stock's Price / Earning ratio at F. This means that ARCH:CA stock's Price/Earning ratio is above 86% of the stocks in the Biotechnology sector in the TSV exchange.
Based on this ARCH:CA may be a overvalued for its sector.
The last closing price of ARCH:CA's stock was CAD 1.24.
The most recent market capitalization for ARCH:CA is CAD 0.07B.
Unfortunately we do not have enough analyst data on ARCH:CA's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARCH:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
